JP7159185B2 - 抗ｐｈｆ－タウ抗体及びその使用 - Google Patents

抗ｐｈｆ－タウ抗体及びその使用 Download PDF

Info

Publication number
JP7159185B2
JP7159185B2 JP2019549574A JP2019549574A JP7159185B2 JP 7159185 B2 JP7159185 B2 JP 7159185B2 JP 2019549574 A JP2019549574 A JP 2019549574A JP 2019549574 A JP2019549574 A JP 2019549574A JP 7159185 B2 JP7159185 B2 JP 7159185B2
Authority
JP
Japan
Prior art keywords
tau
seq
antigen
antibody
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513804A5 (enExample
JP2020513804A (ja
Inventor
マーケン，マーク
マリア，トーマス
ボージャーズ，マリアンヌ
コレン，クリストフ ヴァン
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2020513804A publication Critical patent/JP2020513804A/ja
Publication of JP2020513804A5 publication Critical patent/JP2020513804A5/ja
Priority to JP2022164041A priority Critical patent/JP2022191383A/ja
Application granted granted Critical
Publication of JP7159185B2 publication Critical patent/JP7159185B2/ja
Priority to JP2024055230A priority patent/JP2024088689A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019549574A 2017-03-16 2018-03-16 抗ｐｈｆ－タウ抗体及びその使用 Active JP7159185B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022164041A JP2022191383A (ja) 2017-03-16 2022-10-12 抗ｐｈｆ－タウ抗体及びその使用
JP2024055230A JP2024088689A (ja) 2017-03-16 2024-03-29 抗ｐｈｆ－タウ抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472214P 2017-03-16 2017-03-16
US62/472,214 2017-03-16
PCT/US2018/022782 WO2018170351A1 (en) 2017-03-16 2018-03-16 Anti-phf-tau antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022164041A Division JP2022191383A (ja) 2017-03-16 2022-10-12 抗ｐｈｆ－タウ抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2020513804A JP2020513804A (ja) 2020-05-21
JP2020513804A5 JP2020513804A5 (enExample) 2021-04-15
JP7159185B2 true JP7159185B2 (ja) 2022-10-24

Family

ID=63521020

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019549574A Active JP7159185B2 (ja) 2017-03-16 2018-03-16 抗ｐｈｆ－タウ抗体及びその使用
JP2022164041A Withdrawn JP2022191383A (ja) 2017-03-16 2022-10-12 抗ｐｈｆ－タウ抗体及びその使用
JP2024055230A Withdrawn JP2024088689A (ja) 2017-03-16 2024-03-29 抗ｐｈｆ－タウ抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022164041A Withdrawn JP2022191383A (ja) 2017-03-16 2022-10-12 抗ｐｈｆ－タウ抗体及びその使用
JP2024055230A Withdrawn JP2024088689A (ja) 2017-03-16 2024-03-29 抗ｐｈｆ－タウ抗体及びその使用

Country Status (22)

Country Link
US (3) US10766953B2 (enExample)
EP (1) EP3596119A4 (enExample)
JP (3) JP7159185B2 (enExample)
KR (2) KR102695287B1 (enExample)
CN (2) CN117209599A (enExample)
AR (1) AR111288A1 (enExample)
AU (1) AU2018234709B2 (enExample)
CA (1) CA3055598A1 (enExample)
CL (1) CL2019002566A1 (enExample)
EA (1) EA201992038A1 (enExample)
IL (2) IL310464A (enExample)
JO (1) JOP20180021A1 (enExample)
MA (1) MA47789A (enExample)
MX (2) MX2019010922A (enExample)
MY (1) MY205672A (enExample)
PH (1) PH12019501973A1 (enExample)
SG (1) SG11201907754RA (enExample)
TW (1) TWI771389B (enExample)
UA (1) UA128385C2 (enExample)
UY (2) UY37635A (enExample)
WO (1) WO2018170351A1 (enExample)
ZA (2) ZA202101318B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY178142A (en) * 2011-12-20 2020-10-05 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
SG11201808434WA (en) 2016-05-02 2018-10-30 Prothena Biosciences Ltd Antibodies recognizing tau
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
WO2019077500A1 (en) 2017-10-16 2019-04-25 Eisai R&D Management Co., Ltd. ANTI-WATER ANTIBODIES AND USES THEREOF
JP7362636B2 (ja) 2018-03-05 2023-10-17 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｐｈｆ－タウ抗体及びその使用
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
EP3977135A1 (en) * 2019-05-31 2022-04-06 Eli Lilly And Company Compounds and methods targeting human tau
WO2021024209A1 (en) * 2019-08-06 2021-02-11 Aprinoia Therapeutics Inc. Antibodies that bind to pathological tau species and uses thereof
IL297231A (en) * 2020-04-08 2022-12-01 Janssen Biotech Inc Anti-phf-tau antibodies and uses thereof
WO2022013286A1 (en) * 2020-07-14 2022-01-20 Janssen Pharmaceutica Nv Blood-based assay for detecting tauopathy or amyloidogenic disease
WO2022090169A1 (en) * 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Method of safe administration of anti-tau antibody
WO2022090158A1 (en) * 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects
KR20230147034A (ko) * 2021-02-19 2023-10-20 에자이 알앤드디 매니지먼트 가부시키가이샤 항-pt217 타우 항체
AU2022242135A1 (en) 2021-03-26 2023-11-09 Janssen Biotech, Inc. Anti-tau antibodies and uses thereof
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
AU2023342086A1 (en) 2022-09-15 2025-03-13 Voyager Therapeutics, Inc. Tau binding compounds
CN116948023B (zh) * 2023-09-14 2024-02-09 北京凯祥弘康生物科技有限公司 Tau蛋白抗体及其应用
CN116948024B (zh) * 2023-09-14 2024-02-06 北京凯祥弘康生物科技有限公司 抗Tau蛋白的捕获抗体
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508016A (ja) 2008-11-07 2012-04-05 ファブラス エルエルシー 組合せ抗体ライブラリー及びその使用
JP2015500879A (ja) 2011-12-20 2015-01-08 ヤンセン バイオテツク，インコーポレーテツド 抗ＰＨＦ−ｔａｕ抗体及びその使用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP0610330B1 (en) 1991-10-25 1997-06-18 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau
ES2270421T3 (es) 1993-12-21 2007-04-01 Innogenetics N.V. Anticuerpos monoclonales especificos para phf-tau, hibridomas que secretan los mismos, reconocimiento de antigeno por estos anticuerpos y sus aplicaciones.
JPH10506381A (ja) 1994-07-29 1998-06-23 イノジェネティックス・ナムローゼ・フェンノートシャップ 特定のサブクラスまたは形態のホスホリレーションされたｔａｕのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CN1780855B (zh) * 2003-01-24 2011-03-30 应用分子进化公司 人IL-1β拮抗剂
EP2221315A1 (en) 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
AU2005214988A1 (en) 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
KR20140033236A (ko) 2006-08-04 2014-03-17 노바르티스 아게 Ｅｐｈｂ3-특이적 항체 및 이의 용도
JP2010235447A (ja) 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US9968574B2 (en) 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US8748386B2 (en) 2009-06-10 2014-06-10 New York University Immunological targeting of pathological Tau proteins
US8912355B2 (en) 2009-09-29 2014-12-16 University Of Ottawa Heart Institute Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes
JP2013508287A (ja) 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
CN105968206B (zh) 2010-04-09 2020-01-17 Aveo制药公司 抗erbb3抗体
HUE027649T2 (en) 2010-10-07 2016-10-28 Ac Immune Sa Antibodies recognising phospho-tau
EA031698B1 (ru) 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Человеческие анти-тау антитела

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508016A (ja) 2008-11-07 2012-04-05 ファブラス エルエルシー 組合せ抗体ライブラリー及びその使用
JP2015500879A (ja) 2011-12-20 2015-01-08 ヤンセン バイオテツク，インコーポレーテツド 抗ＰＨＦ−ｔａｕ抗体及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Mol. Biol.，2010年，Vol.398，p.214-231

Also Published As

Publication number Publication date
MX2019010922A (es) 2019-11-08
KR20230155025A (ko) 2023-11-09
CN117209599A (zh) 2023-12-12
BR122023021947A2 (pt) 2024-02-20
MY205672A (en) 2024-11-05
KR102695287B1 (ko) 2024-08-13
IL268700A (en) 2019-10-31
EP3596119A4 (en) 2021-01-13
IL310464A (en) 2024-03-01
AU2018234709B2 (en) 2024-10-31
US20180265575A1 (en) 2018-09-20
US11365244B2 (en) 2022-06-21
MA47789A (fr) 2020-01-22
ZA202311412B (en) 2025-04-30
TWI771389B (zh) 2022-07-21
US20210179696A1 (en) 2021-06-17
IL268700B1 (en) 2024-03-01
JP2024088689A (ja) 2024-07-02
KR20190130133A (ko) 2019-11-21
AR111288A1 (es) 2019-06-26
US10766953B2 (en) 2020-09-08
WO2018170351A1 (en) 2018-09-20
TW201900682A (zh) 2019-01-01
WO2018170351A8 (en) 2019-12-19
MX2024015440A (es) 2025-02-10
ZA202101318B (en) 2023-03-29
IL268700B2 (en) 2024-07-01
AU2018234709A1 (en) 2019-08-29
UY40829A (es) 2024-08-15
EA201992038A1 (ru) 2020-02-06
BR112019019049A2 (pt) 2020-04-22
CN110799531B (zh) 2023-08-04
CN110799531A (zh) 2020-02-14
KR102597462B1 (ko) 2023-11-03
CA3055598A1 (en) 2018-09-20
CL2019002566A1 (es) 2019-12-27
JOP20180021A1 (ar) 2019-01-30
UY37635A (es) 2018-09-28
EP3596119A1 (en) 2020-01-22
UA128385C2 (uk) 2024-07-03
BR122023021958A2 (pt) 2024-02-20
SG11201907754RA (en) 2019-09-27
US20230047413A1 (en) 2023-02-16
JP2020513804A (ja) 2020-05-21
JP2022191383A (ja) 2022-12-27
PH12019501973A1 (en) 2020-06-29

Similar Documents

Publication Publication Date Title
JP7159185B2 (ja) 抗ｐｈｆ－タウ抗体及びその使用
KR20210143858A (ko) 피로글루타메이트 아밀로이드-β에 대한 항체 및 이의 용도
JP2023521763A (ja) 抗ｐｈｆ－タウ抗体及びその使用
KR20200130350A (ko) 항-phf-타우 항체 및 이의 용도
US20240150451A1 (en) Anti-tau antibodies and uses thereof
EA049614B1 (ru) Анти-псф-тау-антитела и способы их применения
EA047298B1 (ru) Антитела к phf-тау и их применение
BR122023021958B1 (pt) Anticorpos anti-phf-tau, composição farmacêutica, e método in vitro de produção dos referidos anticorpos
BR112019019049B1 (pt) Anticorpos antiphf-tau, ácido nucleico isolado, vetor, e composição farmacêutica
BR122023021947B1 (pt) Usos de anticorpos anti-phf-tau

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210303

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220920

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221012

R150 Certificate of patent or registration of utility model

Ref document number: 7159185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250